Kangpu Biopharma receives China NMPA’s IND approval for KPG-818 to treat relapsed/refractory multiple myeloma: Hefei, China Saturday, March 1, 2025, 14:00 Hrs [IST] Kangpu Bioph ...

Paris: Sanofi has announced that the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in ...

Sanofi's Sarclisa (isatuximab) has gained approval from Japan’s Ministry of Health, Labour and Welfare for use in conjunction ...

In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible ...

Karyopharm Therapeutics Inc.’s KPTI share price has dipped by 15.06%, which has investors questioning if this is right time ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

Japanese MHLW approves Sarclisa for patients with newly diagnosed multiple myeloma: Paris Wednesday, February 26, 2025, 09:00 Hrs [IST] The Ministry of Health, Labour and Welfare ...

Janssen-Cilag International NV, a Johnson & Johnson company (NYSE:JNJ) announced Friday that an expert panel of the EU drug ...

Kangpu Biopharmaceuticals, Ltd. ('Kangpu') today announced that the Company has received IND approval from the CDE (Center ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

The Ministry of Health, Labour and Welfare (MHLW) in Japan has approved Sarclisa, in combination with bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment of adult patients with newly ...

A new review published in Genes & Diseases explores the pivotal role of the ubiquitin-proteasome system (UPS) in regulating the tumor microenvironment (TME) and driving cancer progression. The study ...